INTRODUCTION
Although the human glucocorticoid receptor (hGR) is ubiquitously expressed, regulation of the hGR gene is complex, leading to differences in the absolute concentration of GR transcript and protein in individual cells (1) (2) (3) . For instance, treatment with glucocorticoids elicits a down-regulation of GR expression in most cells, a process that may help avoid the detrimental effects associated with chronic exposure to these steroids (reviewed in (4)). T-cells are unique in that glucocorticoids induce hGR mRNA and protein, eventually leading to programmed cell death (apoptosis) (5) . Because of their effect on T-cells, glucocorticoids are important therapeutic agents in pathological conditions involving neoplastic T-cells, such as acute lymphoblastic leukemia (ALL) (reviewed in (6) ). Corticosteroid treatment is also effective in patients with pre-B-cell and early-pre-B-cell leukemia as well (7, 8) . Although most patients are initially responsive to glucocorticoid therapy, many are glucocorticoid resistant upon relapse. In a cell line derived from a T-cell ALL patient, deleterious mutations in the GR coding sequence result in glucocorticoid-resistance (reviewed in (9) ). However, very few GR mutations have been identified to date in human patients (reviewed in (10) ).
In other steroid-resistant cells isolated from this cell line that do not harbor such mutations, glucocorticoid resistance may be due to decreased concentrations of functional GR per T-cell (11) . This suggests a disruption of normal GR gene regulation and expression. Because it is clear that the level of functional glucocorticoid receptors correlates positively with the responsiveness of leukemia patients to corticosteroid therapy (7, 8, 12, 13) , elevating the GR level in patient blast cells would likely improve the clinical outcome.
Transcription of the mouse GR gene initiates from at least five different promoter regions (14, 15) . Only a single promoter region (1C) for the hGR gene had been described until recently, when two other hGR promoter regions (1A and 1B) were identified (3, 16, 17) . Regions within the hGR 1A promoter are responsible for the autologous upregulation of the hGR gene by glucocorticoids (18) . Surprisingly, this promoter also contains a site that could confer interferon responsiveness.
Upon binding their respective membrane receptor, interferons (IFNs) initiate a phosphorylation cascade that results in the activation of signal transducers and activators of transcription or STATs (reviewed in (19) ). These transcription factors in turn regulate a number of IFN-responsive genes, including a family of transcription factors termed interferon regulatory factors (IRFs) that are necessary for downstream induction of many other IFN-responsive genes. The consensus interferon response element (IRF-E) for two members of the IRF family (IRF-1 and IRF-2) is G(A)AAA(G or C)(T or C) GAAA(G or C)(T or C) (20) . Although the IRF proteins share significant homology within their DNA binding domains, they display very different biochemical characteristics and activities. IRF-1 has a very short half-life within a cell (30 minutes), while the half-life of IRF-2 is much longer (8 hours)(21). This difference in protein longevity plays a role in regulating the cellular response to IFN. Normally, the more abundant and long-lived IRF-2 (which binds to but does not activate transcription from an IRF-E) effectively competes with IRF-1 (which acts as a transcriptional activator from an IRF-E) and blunts IRF-1 activity. However, IFNs act to rapidly increase the intracellular concentration of IRF-1 protein to levels that can effectively compete for IRF-E binding sites and thus induce IFN responsive genes (22).
Interferons enhance the immune response to viral and bacterial challenges. Interferons are also commonly used in the treatment of leukemia (reviewed in (23)). There are indications that IRF-1 may act as a tumor suppressor, and loss of function mutations in IRF-1 have been implicated in some forms of leukemia and other neoplasias (reviewed in (24)). However the link between IFN, IRF-1 and such pathologies is still unclear. The discovery of an IRF-E within the hGR gene 1A promoter was intriguing, given the importance of glucocorticoids to T-cell physiology.
The studies described here were performed to determine if the IRF-E in the human GR 1A promoter is functional, and if it can be used as a target to improve the apoptotic response of T-lymphoblasts to steroid therapy.
Although the IRF-E of the hGR 1A promoter is functional when driving the expression of a reporter gene, interferon treatment does not enhance glucocorticoid-mediated apoptosis. Rather, glucocorticoids cause a previously unknown inhibition of interferon-induced IRF-1 expression. Endogenous GR transcripts arising from the hGR 1A promoter are
Reverse transcription-polymerase chain reaction (RT-PCR)
Quantification of IRF-1, IRF-2, and GR transcripts in samples of total RNA was done by real-time quantitative RT-PCR (QRT-PCR) with Taqman probes (Applied Biosystems, Foster City, CA) containing 6-carboxyfluorescein at the 5' end and the quencher 6-carboxy-N,N,N',N'-tetramethylrhodamine at the 3' end. Total GR transcripts and GR transcripts containing exon 1A3 were determined as described previously (26). For the IRF-1 assay the forward primer, reverse primer and the Taqman probe had the sequences: 5'-TGAGGAAGGGAAATTACCTGAGG-3', 5'-CACGTTTGTTGGCTGCCA-3', and 5'-TCCGACTGCTCCAAGAGCTTCATGATG-3', respectively. For the IRF-2 assay, the sequences were: 5'-GCGAGCTCTACCCTCTGCAG-3', 5'-TGGGCACACTATCAGTCGTTTC-3', and 5'-TCTCCCCCGTGTCTTCCTATGCAGAAAG-3'. Dilutions of total RNA from CEM-C7 cells were used as relative standards for the IRF-1 and IRF-2 assays. The transcripts were quantified relative to 18S rRNA determined by realtime QRT-PCR as described elsewhere (26).
DNA Constructs
RT-PCR was used to amplify sequences encoding human IRF-1 and IRF-2 proteins using CEM-C7 total RNA.
Oligonucleotide primers (sense: 5'-AATCGATCCTGCAGCACAGC-3'; antisense: 5'-CCAGGATCCCTGCTACGGT-3') were designed to amplify the entire coding sequence of human IRF-1. PCR products were ligated into pCRII (Invitrogen) and sequenced to confirm IRF-1 identity and fidelity. An expression construct (pIRF1) was created by subcloning the coding sequence for human IRF-1 into the EcoRI and Hind III restriction sites of pCMV5. Oligonucleotide primers (sense: 5'-AGCAACACTGGTACCTTGCG-3', Kpn I site in italics; antisense: 5'-AGTCAGAAGCTTAACAGCTC-3', Hind III site in italics) were designed to amplify the entire coding sequence of human IRF-2. An expression construct (pIRF2) was created by digesting the PCR product with Kpn I and Hind III and ligating it into the same sites in pCMV5. Clones were sequenced to confirm IRF-2 identity and fidelity. The hGR 1A IRF-E/pXP-1 luciferase reporter construct (sequence corresponding to nucleotides +41 to +269 of hGR exon 1A) and the hGR IRF-E deletion construct (hGR 1A ∆IRF-E/pXP-1) were created as previously described (3).
Transfections and Luciferase Assays
Luciferase and β-galactosidase (β-gal) assays were performed as described previously (16) with a Fluoroskan Ascent luminometer (Lab Systems, Helsinki, Finland). Luciferase gene expression was normalized to β-galactosidase (β-gal) activity.
To examine the effect of IFN treatment on hGR 1A promoter activity in T-cells, Jurkat cells were seeded in 6-well plates (2 x 10 6 cells/well) and transfected with 1.5 µg of reporter construct (either hGR 1A IRF-E/pXP-1 or hGR 1A ∆IRF-E/pXP-1) and 1 µg of pCMV/ β-gal construct using Superfect transfection reagent (Qiagen). Transfected cells were allowed to grow for 24 hours, at which time 100 U/ml of IFNα, IFNβ, or IFNγ were added to individual wells. Cells were collected 24 hours after IFN addition for determination of luciferase and β-gal activity.
To determine if IRF proteins have a direct role in driving transcription from the hGR 1A promoter, CHOP cells were cotransfected with human IRF expression constructs and hGR 1A promoter constructs. CHOP cells were plated in 6-well plates, grown to 60-80% confluency, and cotransfected with 1 µg reporter construct (empty pXP-1, hGR 1A
IRF-E/pXP-1, or hGR 1A ∆IRF-E/pXP-1), 0.25 µg pCMV/β-gal, and expression construct (1 µg pCMV5, 0.5 µg pIRF1, 0.5 µg pIRF2 or 0.5 µg of both pIRF1 and pIRF2). Empty pCMV5 was added to ensure that all transfections received equal amounts of DNA. Cells were collected 24 hours following transfection as previously described (16) .
Electrophoretic Mobility Shift Assay (EMSA)
Electrophoretic mobility shift assays were performed as previously described using 10 µg of nuclear extract (16) . Nuclear extracts from CEM-C7, Jurkat, and CHOP cells were obtained using the NE-PER kit (Pierce, Rockford, IL). IRF-E consensus oligonucleotide and mutant (eliminating IRF binding) IRF-E oligonucleotide were obtained from Geneka (Montreal, Canada). The hGR 1A IRF-E double stranded oligonucleotide was described previously (3).
Supershift analysis was carried out following incubation at room temperature of the nuclear extracts with 2 µg of IRF-1 or IRF-2 antibody (Santa Cruz Biotechnology) 1 hour prior to addition of labeled oligonucleotides.
LDH Assay
CEM-C7 cells (1 x 10 5 cells/ml in 200 µl total volume) in 96-well tissue culture plates were treated with IFNα, IFNβ, or IFNγ (0, 1, 10, 100, 500 and 1000 U/ml) in 2 µl phosphate buffered saline (PBS) or dexamethasone (0, 1, 10, 100, 500 and 1000 nM) in 2 µl ethanol. To examine the effect of combinatorial treatment, other experiments were conducted with cells treated as described above, except IFN dose response experiments also received 10 nM dexamethasone in 2 µl ethanol and dexamethasone dose response experiments also received 100 U/ml IFN in 2 µl PBS.
Following a 48-hour incubation, cells were collected by centrifugation and lactate dehydrogenase (LDH) activity in the media was determined from an aliquot of the supernatant, as described by the manufacturer (Sigma reagent #228-500P, 
Flow cytometric viability assay
CEM-C7 cells were seeded in 6-well plates in 3 ml aliquots at a cell concentration of 2.5 x 10 5 cells/ml and treated with IFNγ, dexamethasone or a combination of both in 0.3 ml media. Cell viability was assessed after 48 and 72 hours by flow cytometry using the Vybrant TM Apoptosis Assay Kit #4 (V-13243; Molecular Probes). The assay was conducted essentially according to the manufacturer's guidelines, except that a PBS wash was not conducted before staining, as a preliminary experiment indicated that this wash had essentially no effect on staining or viability. Measurements were 
RESULTS

Treatment with IFNγ increases IRF-1 protein and binding of IRF-1 to the hGR 1A IRF-E
The discovery of an IRF-E in the hGR 1A promoter suggested IFN regulation of GR gene expression, most likely through the transcription factor IRF-1. Treatment of CEM-C7 and Jurkat (see below) cells with IFNγ induced IRF-1 protein in a time-and dose-dependent manner (Fig. 1A) . The two bands seen may represent different forms of IRF-1 due to posttranslational modification or partial proteolysis. Transfection studies with an IRF-1 cDNA into CHOP cells gave the same two bands, indicating that these two bands are both authentic IRF-1 (see Fig, 3 , below).
EMSA was used to determine if IRF proteins bind the IRF-E within the hGR 1A promoter. Previous studies had shown that an unlabeled hGR 1A IRF-E or an unlabeled consensus IRF-E could compete for binding of nuclear proteins to the labeled hGR 1A oligonucleotide (3), while competition was lost if the IRF-E was deleted. The same results were obtained when a consensus IRF-E was used as the labeled probe for EMSA instead of the hGR 1A IRF-E (data not shown). In the current study, proteins within CEM-C7 and Jurkat cell nuclear extracts bind to and retard the mobility of labeled 1A IRF-E oligonucleotide ( These results indicate that IRF-2, present in both untreated and IFNγ-treated CEM-C7 and Jurkat cells, is able to bind to the hGR 1A IRF-E. IRF-1 is also able to bind the hGR 1A IRF-E, but it is unable to form protein-DNA complexes, as analyzed by EMSA, in untreated cells. However, IFNγ strongly induces IRF-1 levels, and this results in easily detectable IRF-1 protein complexes with the hGR 1A IRF-E.
IFNs induce transcription from an hGR 1A IRF-E reporter construct in Jurkat cells
In order to examine whether IFN induces transcription from the IRF-E in the hGR 1A promoter, Jurkat cells were transfected with a hGR 1A promoter reporter construct containing the IRF-E and subsequently treated with 100 U/ml each of IFNα, IFNβ, or IFNγ. Jurkat cells were used because CEM-C7 cells are very difficult to transfect.
Cloning of the +41/+269 hGR 1A sequence into the pXP-1 vector increases basal transcription about 5-fold compared to the empty vector (data not shown). All three IFNs induce luciferase activity from the hGR 1A IRF-E promoter construct, although IFNγ was more potent than IFNα or IFNβ (Fig. 2 ). This concentration of IFNγ is sufficient to cause increases IRF-1 binding to the IRF-E in an EMSA, and substantially induces both IRF-1 protein and mRNA in
Jurkat cells (see Figs. 6 and 7, below). Deletion of the hGR 1A IRF-E from the promoter sequence completely abolished IFN induction of luciferase transcription (Fig. 2) . These results indicate that interferons induce transcription from the hGR 1A IRF-E reporter construct transiently transfected into human T-lymphoblast cells.
Heterologously expressed IRF-1 drives transcription from the hGR 1A IRF-E
To examine if heterologously expressed IRF-1 and IRF-2 would bind the hGR 1A IRF-E, nuclear extracts were isolated from CHOP cells 24 hours after transfection with either pIRF-1 or pIRF-2 cDNA. Western blotting of cell extracts indicated that this period was sufficient for high-level expression of both proteins (Fig. 3A) . As seen previously for the western blot with endogenous IRF-1 protein (Fig. 1A) , two bands of IRF-1 are detected. Both the hGR 1A IRF-E and consensus IRF-E oligonucleotides (data not shown) were shifted by nuclear extracts from CHOP cells transfected with pIRF1 or pIRF2 ( 
Interferons do not increase the sensitivity of CEM-C7 cells to glucocorticoids
Because interferons could potentially increase the sensitivity of T-cells to glucocorticoids by increasing intracellular GR concentrations through the human GR 1A promoter, we examined the response of CEM-C7 cells to DEX in the presence and absence of IFNs. Results of the LDH assay indicate that treatment with 100-1000 nM DEX for 48 hours results in 10-15% CEM-C7 cell mortality. There was no significant difference between cells treated with DEX and those treated with DEX and 100 U/ml IFNγ (Fig. 5A) . Similar results were obtained with IFNα and IFNβ (data not shown). IFN treatment alone appeared to have no effect on cell viability, while treatment of cells with IFN and 10 nM DEX resulted in the same level of cell death as when cells were treated with 10 nM DEX alone.
The MTS assay, a more sensitive method of detecting cell viability, indicated that treatment with DEX resulted in higher CEM-C7 cell mortality (20-40%). However, there again were no significant differences between cells treated with DEX alone and cells treated with DEX and IFNγ (only the effects of IFNγ were examined with this assay) (Fig.   5B ).
Analysis of CEM-C7 cells with flow cytometry yielded similar results (Fig. 5C ). Dose response curves using DEX in the presence or absence of 100 U/ml of IFNγ were indistinguishable at either 48 or 72 hr of treatment; no leftshifting of the dose response cell death curve occurred with IFNγ treatment. In a complementary experiment, CEM-C7 cells were treated with 10 nM dexamethasone (a dose that only slightly impairs cell viability) and varying doses of IFNγ. Again, no effect of IFNγ was observed on CEM-C7 cell viability (data not shown). These results indicate that
IFNs do not alter the sensitivity of these CEM-C7 T-lymphoblasts to glucocorticoids.
Dexamethasone blocks IFNγ induction of IRF-1 mRNA and protein
We were perplexed by the fact that the hGR 1A IRF-E appeared to be perfectly functional and yet IFNγ did not affect the apoptotic response of T-lymphoblasts to glucocorticoids. Thus, we quantitatively reexamined the regulation of IRF-1 and IRF-2 mRNA and protein expression. Quantitative western blots indicated a 4.6-fold increase in IRF-1 protein in Jurkat cells treated with IFNγ, while there was no significant increase in IRF-2 protein (Fig. 6A) . The IFNγ-induced increase in IRF-1 mRNA and protein levels is consistent with the increase in IRF-1 binding to the IRF-E observed previously by EMSA (Fig. 1B) . IFNγ also increased IRF-1 protein in CEM-C7 cells (Fig. 6B ), but the induction was not as robust (2.6-fold) as in Jurkat cells. IRF-2 protein levels were not affected by IFNγ-treatment.
DEX alone reduced the amount of IRF-1 protein by about 50% and also caused a 50% increase in IRF-2 levels.
Surprisingly, the IFNγ induction of IRF-1 protein levels was completely blocked when CEM-C7 cells were simultaneously treated with DEX (Fig. 6B) , while there was a small, but not significant, increase in IRF-2 protein.
Even though DEX blocked induction of IRF-1, the hGR protein levels were still induced 3.2-fold by DEX in the presence of IFNγ, similar to that observed previously for DEX-treatment alone( Fig. 6B; (26) ). Recent studies have identified the steroid hormone-responsive sequences in the hGR 1A promoter, and these are apparently not dependent upon the activity of the hGR 1A IRF-E (18). IFNγ-treatment alone also did not induce hGR protein levels (Fig. 6B) .
These results were confirmed and extended at the mRNA level using QRT-PCR. There was an excellent correlation between the amount of IFNγ induction of IRF-1 mRNA levels in CEM-C7 (3.1-fold) and Jurkat (5-fold) cells (Fig. 7A) , when compared to protein induction levels for these cell lines (Fig. 6) . Furthermore, IFNα and IFNβ, from a variety of sources, were not able to induce IRF-1 mRNA. IRF-2 was relatively unaffected by treatment with interferons, although a slight increase was observed in both cell lines with IFNγ-treatment (Fig. 7B) . promoter was apparently non-responsive, as transcripts derived from this promoter were not affected by any interferon that was tested (Fig. 7C) . Thus, even though transiently transfected reporter genes containing the hGR 1A promoter are responsive to IFNγ induction, the endogenous hGR 1A promoter IRF-E is not. Finally, we confirmed that the inhibition of IRF-1 protein levels by DEX alone and by DEX in IFNγ-treated cells (Fig. 6B) was mediated at the level of IRF-1 gene transcription, as DEX completely blocked IFNγ-induction of IRF-1 mRNA in CEM-C7 cells (Fig. 8) .
DISCUSSION
The purpose of these studies was to determine how the human GR 1A promoter/exon sequence is regulated by interferons and to elucidate the transcription factors and signal transduction pathways that are involved. Others had shown that up-regulation of GR protein levels is required for the apoptotic response in T-lymphoblasts (27). Thus, a long-term goal of our research is to improve therapy in patients with T-cell acute lymphocytic leukemia (ALL) by upregulating GR protein levels via treatment with steroid plus other biological response modifiers that stimulate GR 1A
promoter activity.
The GR 1A promoter/exon contains an intraexonic sequence that was nearly identical to the consensus DNA binding sequence for the interferon stimulated transcription factor, IRF-1 (3). This was particularly interesting, because glucocorticoids and interferons have opposing effects systemically. That is, corticosteroids are generally antiinflammatory, inhibit cell division, and promote cellular differentiation, while interferons are proinflammatory and often stimulate cell proliferation. Thus, it was hoped that the combined treatment of T-cell ALL patients with steroid and interferon would cause a synergistic or additive effect on T-lymphoblast cell death, while the opposing actions of the two drugs systemically would spare the patient from the untoward side effects resulting from either drug alone. (although not statistically significant) the cotransfection of both IRF-1 and IRF-2 cDNAs seemed to diminish the effect of IRF-1. Perhaps IRF-2 was unable to compete effectively with IRF-1 because IRF-1 is expressed at higher levels than IRF-2 24 hours after transfection (Fig. 3A) . These experiments clearly show that the hGR 1A IRF-E is a bona fide
Interferon Regulatory Factor Response Element. Indeed, there is a CpG sequence in the IRF-E that would be a substrate for the methylase used in these studies, and in vitro methylation of the hGR 1A IRF-E/pXP-1 luciferase reporter construct abolishes its ability to be activated by interferon treatment (C.-d. Geng and W.V. Vedeckis, data not shown). It is, however, possible that this IRF-E could be functional in cell types other than T-cells.
In summary, the hGR gene 1A promoter contains a functional IRF-E. However, it appears that this promoter element is silenced in at least two T-lymphoblast cell lines. This may be a mechanism to ensure that hormones with opposing actions (glucocorticoids and interferons) do not yield the same response (up-regulation of the GR gene) in these cell types. A second mechanism to insure that these two pathways do not result in the same signaling is the blocking of IFNγ-induced IRF-1 gene activation by glucocorticoids. Although the interferon and steroid activated pathways apparently cannot be used in concert to improve the killing of T-cell ALL cells, it is hoped that future studies will reveal a signaling pathway that can activate hGR gene expression and improve the apoptotic response of these cancer cells to hormone. 
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